圣诺生物部分产品拟中选新一轮接续采购

Core Viewpoint - Shengnuo Biopharmaceutical (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation procurement for chemical drugs [1] Group 1 - The continuation procurement is based on the results of the "Proposed Selected Results for Continuation Procurement of Expired National Organized Procurement Drugs" [1] - The company's products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] - New products selected for this round include Thymosin Alpha 1 Injection and Exenatide Injection, which are also part of the proposed selections [1]